PMC 10215789
The byproducts of 5-hydroxytryptamine (5-HT) neurons may cause gastrointestinal dysfunction (GID) concomitant with DA precursor neuron differentiation from iPSCs
Safety, Timing, and Monitoring Requirements for Combination Use No direct drug-drug interaction exists between inositol and GLP-1 agonists at the pharmacokinetic level, meaning absorption, metabolism, and excretion are independent
Orlistat, a lipase inhibitor approved in 1999, blocks dietary fat absorption but produces minimal weight loss (3-5% body weight) and causes uncomfortable gastrointestinal side effects like urgency and oily spotting
Cigna: Certain plans cover tirzepatide, especially for those with obesity or accompanying conditions like type 2 diabetes
Market Overview The Liraglutide and Semaglutide Market was valued at USD 15.19 billion in 2024 and is projected to reach USD 35.01 billion by 2032, expanding at a CAGR of 11% during the forecast period